Cardiac Science raises $8.7 million:
This article was originally published in Clinica
Cardiac Science has raised $8.7 million through a private placement. The Irvine, California-based company claims it has developed the only external defibrillator that continuously monitors in-hospital patients at risk of sudden cardiac arrest. If necessary, the product administers a shock within seconds, without the aid of hospital staff. The company will use the proceeds for the global marketing of its Powerheart ECD, which it plans to launch this quarter.
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.